Clinical trials: Ascites, Malignant
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Malignant Ascites, Gastrointestinal Cancers
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Malignant ascites represents a severe clinical problem for physicians and patients being confronted with this common symptom of advanced-stage gastrointestinal cancer.
- Trial name
- NCT01200121
- Testing
- Bevacizumab
- Where
- 26 sites in Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
This study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer.
- Trial name
- IPIZA (NCT06759064)
- Testing
- zoledronic acid plus Sintilimab intraperitoneal injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Qilu Hospital of Shandong University
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.
- Trial name
- NCT00836654
- Testing
- Catumaxomab (Removab), paracentesis
- Volunteers
- 258 people
- Sponsor
- Neovii Biotech
Malignancy, Pleural Effusion
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
The purpose of the current study is to establish a Liquid biopsy method (positive enrichment by a novel immunomagnetic beads capture assay) for detection of malignant cell in serous effusions and to evaluate its sensitivity and…
- Conditions
- Malignancy, Pleural Effusion, Pleural Diseases, Ascites
- Trial name
- NCT02891642
- Testing
- Immunomagnetic Detection
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Refractory Malignant Ascites
Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Malignant ascites leads to significant morbidity in patients with terminal cancer. Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of…
- Trial name
- NCT02477657
- Testing
- Paracentesis, Tunneled Intraperitoneal Drain (IPD), Peritoneal-Venous shunts (PVS)
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastric Cancer, Stomach Neoplasms
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites
- Trial name
- NCT03475615
- Testing
- Oxaliplatin, Paclitaxel, S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
- Where
- China
- Volunteers
- 215 people
- Sponsor
- Fudan University
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Fallopian Tube Cancer, Metastatic Cancer
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002960
- Testing
- recombinant adenovirus-p53 SCH-58500
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Pleural Effusion, Pleural Effusion, Malignant
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
The goal of this observational study is to learn about the performance of the drainova® ArgentiC Catheter in clinical routine, which is used to treat fluid accumulations in hollow body structures.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Ascites, Ascites, Malignant
- Trial name
- NCT06436807
- Testing
- Indwelling catheter
- Where
- 12 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ewimed GmbH
Malignant Ascites
Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.
The purpose of this study is to determine whether drainage with the usage of a fine, patient-controlled vascular catheter inserted into abdominal cavity is a feasible, safe and effective method in the management of symptomatic…
- Trial name
- NCT02724683
- Testing
- Ascites drainage with vascular catheter., Interview., Quality of life.
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 170 people
- Sponsor
- Maciej Stukan, MD, PhD
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Malignant Ascites
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by…
- Trial name
- NCT06200376
- Testing
- T3011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Stomach Neoplasms, Peritoneal Metastasis
The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites
This is a clinical Study to evaluate the effect, survival benefit and safety of intraperitoneal docetaxel combined with oral S-1 for advanced gastric cancer with malignant ascites.
- Trial name
- NCT02779608
- Testing
- intraperitoneal docetaxel, oral S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Cancer
Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
While some authors recommend diuretics as the first treatment to initiate for symptoms caused by malignant ascites (MA), their prescription is variable. No randomized, controlled study has assessed their benefit in this context.
- Trial name
- NCT02501213
- Testing
- Spironolactone (+/- Furosemide)
- Where
- 15 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Oscar Lambret
Advanced Solid Tumors
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Study Population: Adult subjects aged 18-75 years with relapsed/refractory advanced solid tumors (including liver, gastric, colorectal, ovarian cancer, etc.) and malignant ascites confirmed by cytology, who have failed at least 2…
- Trial name
- NCT07561437
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Cirrhosis, Ascites Hepatic
PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small volume fluid drainage at home. The treatment may improve the management of ascites and have a beneficial effect on the quality of life.
- Conditions
- Cirrhosis, Ascites Hepatic, Ascites (Non-Malignant)
- Trial name
- PETRA (NCT03027635)
- Testing
- PleurX, peritoneal tunnelated catheter, Large Volume Paracentesis, Ciprofloxacin 500Mg Tablet
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Nina Kimer
Malignant Ascites
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites.
- Trial name
- NCT05501340
- Testing
- Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Soochow University